Alnylam Pharmaceuticals | ALNY - Ebitda



金融业
股票价格
USD
资产
USD 5.56B
现金及等价物
USD 1.71B
销售成本
USD 298.45M
流动资产
USD 4.62B
流动负债
USD 1.51B
债务
USD 1.27B
EBIT
USD 112.6M
EBITDA
USD 245.34M
员工
2.23K
EPS每股收益
USD 1.84
股本和储备
USD 1.35B
销售毛利
USD 992.69M
债务利息支出
USD 82.05M
利息收入
USD 26.6M
贷款资金
USD 2.47B
市值
USD 32.01B
净收入
USD 164.49M
营业费用
USD 1.06B
营业利润
USD 112.6M
普通股股本
USD 133.73M
PE价格收益
75.64
税前利润
USD 177.81M
销售收入
USD 1.29B
销售和管理费用
USD 347.92M
股票
USD 97.11M
贸易债权人
USD 108.02M
应收帐款人
USD 912.74M


Ebitda 更改 日
Acadia Pharmaceuticals USD -1.62M 21.94M 2026-03
Agios Pharmaceuticals USD -108.66M 11.65M 2026-03
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Amgen USD 3.86B 1.28B 2026-03
Arrowhead Research USD -147.68M 40.33M 2026-06
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Incyte USD 778.57M 410.6M 2026-06
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
Moderna USD -1.26B 468M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 5.41B 431M 2026-03
PTC Therapeutics USD 61.98M 132.97M 2026-03
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Sanofi EUR 2.72B 2.94B 2026-03
Sarepta Therapeutics USD 375.48M 627.68M 2026-03
Takeda JPY 364.46B 214.21B 2026-06
Tectonic Therapeutic USD -21.18M 365K 2025-12
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
Vertex Pharmaceuticals USD 1.33B 130.5M 2026-06
Xencor USD -34.63M 86.74M 2026-06